EMA Authorised: Mircera (Methoxy polyethylene glycol-epoetin beta) — Roche Registration GmbH

View source ↗

Summary

Mircera (Methoxy polyethylene glycol-epoetin beta) has been authorised for anemia associated with chronic kidney failure in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia Due to Chronic Kidney Failure

Drugs mentioned

• MIRCERA (METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA)

Snippet

Status: Authorised. Therapeutic area: Anemia;Kidney Failure, Chronic. MAH: Roche Registration GmbH. Decision date: 15/01/2026